Justin Penner1, Omar Abdel-Mannan2, Karlie Grant1, Sue Maillard3, Filip Kucera4, Jane Hassell5, Michael Eyre6, Zoe Berger7, Yael Hacohen2, Karyn Moshal8. 1. Department of Paediatric Infectious Diseases, Great Ormond Street Hospital, London, UK. 2. Department of Paediatric Neurology, Great Ormond Street Hospital, London, UK; Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK. 3. Department of Physiotherapy and Rehabilitation Services, Great Ormond Street Hospital, London, UK. 4. Department of Paediatric Cardiology, Great Ormond Street Hospital, London, UK. 5. Department of Paediatric Infectious Diseases, Great Ormond Street Hospital, London, UK; Department of Paediatric Neurology, Great Ormond Street Hospital, London, UK; Department of General Paediatrics, Great Ormond Street Hospital, London, UK. 6. Department of Paediatric Neurology, Great Ormond Street Hospital, London, UK. 7. Department of Clinical Psychology, Great Ormond Street Hospital, London, UK. 8. Department of Paediatric Infectious Diseases, Great Ormond Street Hospital, London, UK; UCL Great Ormond Street Institute of Child Health, University College London, London, UK. Electronic address: karyn.moshal@gosh.nhs.uk.
Abstract
BACKGROUND: Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) is a new, rare, post-infectious complication of SARS-CoV-2 infection in children. We aimed to describe the 6-month outcomes of PIMS-TS. METHODS: This retrospective cohort study comprised children (aged <18 years) who fulfilled the UK Royal College of Paediatrics and Child Health (RCPCH) diagnostic criteria for PIMS-TS and were admitted to Great Ormond Street Hospital (London, UK) between April 4 and Sept 1, 2020. Patients were followed up by a multidisciplinary team of specialists at 6 weeks and 6 months after admission. Biochemical and functional outcomes were analysed. FINDINGS: 46 children were included in this study. The median age at presentation was 10·2 years (IQR 8·8-13·3), 30 (65%) patients were male and 16 (35%) were female, 37 (80%) were from minority ethnic groups, and eight (17%) had pre-existing comorbidities. All patients had elevated markers of systemic inflammation at baseline. None of the patients died. By 6 months, systemic inflammation was resolved in all but one patient. 38 (90%) of 42 patients who had positive SARS-CoV-2 IgG antibodies within 6 weeks of admission remained seropositive at 6 months. Echocardiograms were normal in 44 (96%) of 46 patients by 6 months, and gastrointestinal symptoms that were reported in 45 (98%) of 46 patients at onset were present in six (13%) of 46 patients at 6 months. Renal, haematological, and otolaryngological findings largely resolved by 6 months. Although minor abnormalities were identified on neurological examination in 24 (52%) of 46 patients at 6 weeks and in 18 (39%) of 46 at 6 months, we found minimal functional impairment at 6 months (median Expanded Disability Status Scale score 0 [IQR 0-1]). Median manual muscle test-8 scores improved from 53 (IQR 43-64) during hospital admission to 80 (IQR 68-80) at 6 months, but 18 (45%) of 40 patients showed 6-min walk test results below the third centile for their age or sex at 6 months. PedsQL responses revealed severe emotional difficulties at 6 months (seven [18%] of 38 by parental report and eight [22%] of 38 by self report). 45 (98%) of 46 patients were back in full-time education (virtually or face to face) by 6 months. INTERPRETATION: Despite initial severe illness, few organ-specific sequelae were observed at 6 months. Ongoing concerns requiring physical re-conditioning and mental health support remained, and physiotherapy assessments revealed persisting poor exercise tolerance. Longer-term follow-up will help define the extended natural history of PIMS-TS. FUNDING: None.
BACKGROUND: Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) is a new, rare, post-infectious complication of SARS-CoV-2 infection in children. We aimed to describe the 6-month outcomes of PIMS-TS. METHODS: This retrospective cohort study comprised children (aged <18 years) who fulfilled the UK Royal College of Paediatrics and Child Health (RCPCH) diagnostic criteria for PIMS-TS and were admitted to Great Ormond Street Hospital (London, UK) between April 4 and Sept 1, 2020. Patients were followed up by a multidisciplinary team of specialists at 6 weeks and 6 months after admission. Biochemical and functional outcomes were analysed. FINDINGS: 46 children were included in this study. The median age at presentation was 10·2 years (IQR 8·8-13·3), 30 (65%) patients were male and 16 (35%) were female, 37 (80%) were from minority ethnic groups, and eight (17%) had pre-existing comorbidities. All patients had elevated markers of systemic inflammation at baseline. None of the patientsdied. By 6 months, systemic inflammation was resolved in all but one patient. 38 (90%) of 42 patients who had positive SARS-CoV-2 IgG antibodies within 6 weeks of admission remained seropositive at 6 months. Echocardiograms were normal in 44 (96%) of 46 patients by 6 months, and gastrointestinal symptoms that were reported in 45 (98%) of 46 patients at onset were present in six (13%) of 46 patients at 6 months. Renal, haematological, and otolaryngological findings largely resolved by 6 months. Although minor abnormalities were identified on neurological examination in 24 (52%) of 46 patients at 6 weeks and in 18 (39%) of 46 at 6 months, we found minimal functional impairment at 6 months (median Expanded Disability Status Scale score 0 [IQR 0-1]). Median manual muscle test-8 scores improved from 53 (IQR 43-64) during hospital admission to 80 (IQR 68-80) at 6 months, but 18 (45%) of 40 patients showed 6-min walk test results below the third centile for their age or sex at 6 months. PedsQL responses revealed severe emotional difficulties at 6 months (seven [18%] of 38 by parental report and eight [22%] of 38 by self report). 45 (98%) of 46 patients were back in full-time education (virtually or face to face) by 6 months. INTERPRETATION: Despite initial severe illness, few organ-specific sequelae were observed at 6 months. Ongoing concerns requiring physical re-conditioning and mental health support remained, and physiotherapy assessments revealed persisting poor exercise tolerance. Longer-term follow-up will help define the extended natural history of PIMS-TS. FUNDING: None.
Authors: Aleksandra Stasiak; Piotr Kędziora; Beata Kierzkowska; Katarzyna Niewiadomska-Jarosik; Ewelina Perdas; Elżbieta Smolewska Journal: Int J Cardiol Date: 2022-05-14 Impact factor: 4.039
Authors: Veronica Davalos; Carlos A García-Prieto; Gerardo Ferrer; Sergio Aguilera-Albesa; Juan Valencia-Ramos; Agustí Rodríguez-Palmero; Montserrat Ruiz; Laura Planas-Serra; Iolanda Jordan; Iosune Alegría; Patricia Flores-Pérez; Verónica Cantarín; Victoria Fumadó; Maria Teresa Viadero; Carlos Rodrigo; Maria Méndez-Hernández; Eduardo López-Granados; Roger Colobran; Jacques G Rivière; Pere Soler-Palacín; Aurora Pujol; Manel Esteller Journal: EClinicalMedicine Date: 2022-06-25
Authors: James Wong; Paraskevi Theocharis; William Regan; Kuberan Pushparajah; Natasha Stephenson; Emma Pascall; Aoife Cleary; Laura O'Byrne; Alex Savis; Owen Miller Journal: Pediatr Cardiol Date: 2022-04-29 Impact factor: 1.838
Authors: Ronan Lordan; Samantha Prior; Elizabeth Hennessy; Amruta Naik; Soumita Ghosh; Georgios K Paschos; Carsten Skarke; Kayla Barekat; Taylor Hollingsworth; Sydney Juska; Liudmila L Mazaleuskaya; Sarah Teegarden; Abigail L Glascock; Sean Anderson; Hu Meng; Soon-Yew Tang; Aalim Weljie; Lisa Bottalico; Emanuela Ricciotti; Perla Cherfane; Antonijo Mrcela; Gregory Grant; Kristen Poole; Natalie Mayer; Michael Waring; Laura Adang; Julie Becker; Susanne Fries; Garret A FitzGerald; Tilo Grosser Journal: Front Public Health Date: 2021-12-16
Authors: Daisuke Matsubara; Joyce Chang; Hunter L Kauffman; Yan Wang; Sumekala Nadaraj; Chandni Patel; Stephen M Paridon; Mark A Fogel; Michael D Quartermain; Anirban Banerjee Journal: J Am Heart Assoc Date: 2022-01-19 Impact factor: 6.106